Clinical Trials

HIV Emergency Treatment IND and Phase II/III Trials Filed

Published in AIDS Weekly, March 6th, 2000

Hemispherx Biopharma, Inc., announced that it has filed for HIV Emergency Treatment IND and Phase II and Phase III trials with the U.S. Food and Drug Administration (FDA).

The company's new HIV Emergency Treatment IND application is intended to be used to study the effects of Ampligen on the growing number of people with AIDS who are developing resistance to their currently approved regimens, some of whom have been left with no other clinical options. Hemispherx's Phase II and Phase III trials are intended to study the effects of Ampligen in combination with several Highly Active Antiretroviral Therapy (HAART) regimens, which have been structured by Anderson Clinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-03-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry